This invention is developed by the University of Málaga (UMA) in collaboration with Andalusian Public Health System and CIBER. Method that allows differentiating the degree of activity and severity of rheumatioid arthritis, in order to predict the prognosis of patients who suffer from it.
Currently there are no early diagnostic methods that detect rheumatoid arthritis (RA) because the diagnosis of this disease can be complicated in its early stages because the first signs and symptoms are similar to many other chronic inflammatory autoimmune diseases. In the research results that have led to this patent, a microbiota population has been identified that is increased in patients with RA and decreased in healthy patients. For this reason, these populations have been chosen for the early diagnosis of suffering from an autoimmune inflammatory disease. The chosen microorganisms can act as biomarkers of RA, which allow us to differentiate the severity or degree of activity of the disease. Likewise, it is contemplated to develop commercial diagnostic kits such as probiotic, prebiotic and nutraceutical substances with said bacteria in order to improve the patient's microbiota profile and finally the problems associated with the disease.
Desired business relationship
Other : Collaborative projects
Current development status
Commercial diagnostic kits